This phase I/IIb trial is trying to understand whether an adjuvant immunotherapy is safe, tolerable and effective for patients who have had a stage III or stage IV melanoma removed, but are at high risk of it coming back.
This trial is treating patients with stage IIIB/IIIC/IIID or stage IV melanoma.
This is a systemic therapy trial.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
- You have had certain treatments, surgical procedures or drugs.
- You have previously been treated (or are currently being treated) on a clinical trial.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Phase 1/2, Study of Adjuvant Immunotherapy With EVX-02 and Anti-PD-1 After Complete Resection of Stage IIIB/IIIC/IIID or Stage IV Melanoma in Patients at High Risk for Recurrence
Evaxion Biotech A/S
This study will be conducted in two parts. All patients will receive anti-PD-1 once every 4 weeks for up to 1 year commencing on Day 1 and with EVX-02 vaccine as soon as it is produced. Part 1 will consist of two cohorts - patients in Cohort A will receive EVX- 02A and patients in Cohort B will receive EVX- 02B. Part 2 (Cohort C) will be an expansion cohort. In this part, only one delivery method, either EVX-02A or EVX-02B with will be used.
Recruiting Hospitals Read More
Not Recruiting Hospitals Read More